Literature DB >> 21266548

Molecular basis for ubiquitin and ISG15 cross-reactivity in viral ovarian tumor domains.

Masato Akutsu1, Yu Ye, Satpal Virdee, Jason W Chin, David Komander.   

Abstract

Crimean Congo hemorrhagic fever virus (CCHFV) is a deadly human pathogen that evades innate immune responses by efficiently interfering with antiviral signaling pathways mediated by NF-κB, IRF3, and IFNα/β. These pathways rely on protein ubiquitination for their activation, and one outcome is the modification of proteins with the ubiquitin (Ub)-like modifier interferon-stimulated gene (ISG)15. CCHFV and related viruses encode a deubiquitinase (DUB) of the ovarian tumor (OTU) family, which unlike eukaryotic OTU DUBs also targets ISG15 modifications. Here we characterized the viral OTU domain of CCHFV (vOTU) biochemically and structurally, revealing that it hydrolyzes four out of six tested Ub linkages, but lacks activity against linear and K29-linked Ub chains. vOTU cleaved Ub and ISG15 with similar kinetics, and we were able to understand vOTU cross-reactivity at the molecular level from crystal structures of vOTU in complex with Ub and ISG15. An N-terminal extension in vOTU not present in eukaryotic OTU binds to the hydrophobic Ile44 patch of Ub, which results in a dramatically different Ub orientation compared to a eukaryotic OTU-Ub complex. The C-terminal Ub-like fold of ISG15 (ISG15-C) adopts an equivalent binding orientation. Interestingly, ISG15-C contains an additional second hydrophobic surface that is specifically contacted by vOTU. These subtle differences in Ub/ISG15 binding allowed the design of vOTU variants specific for either Ub or ISG15, which will be useful tools to understand the relative contribution of ubiquitination vs. ISGylation in viral infection. Furthermore, the crystal structures will allow structure-based design of antiviral agents targeting this enzyme.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21266548      PMCID: PMC3038727          DOI: 10.1073/pnas.1015287108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family.

Authors:  Anna Borodovsky; Huib Ovaa; Nagamalleswari Kolli; Tudeviin Gan-Erdene; Keith D Wilkinson; Hidde L Ploegh; Benedikt M Kessler
Journal:  Chem Biol       Date:  2002-10

2.  Crimean-Congo hemorrhagic fever virus-encoded ovarian tumor protease activity is dispensable for virus RNA polymerase function.

Authors:  Eric Bergeron; César G Albariño; Marina L Khristova; Stuart T Nichol
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

3.  Lys11-linked ubiquitin chains adopt compact conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne.

Authors:  Anja Bremm; Stefan M V Freund; David Komander
Journal:  Nat Struct Mol Biol       Date:  2010-07-11       Impact factor: 15.369

4.  Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU deubiquitinase.

Authors:  Satpal Virdee; Yu Ye; Duy P Nguyen; David Komander; Jason W Chin
Journal:  Nat Chem Biol       Date:  2010-08-29       Impact factor: 15.040

Review 5.  Emerging role of ISG15 in antiviral immunity.

Authors:  Brian Skaug; Zhijian J Chen
Journal:  Cell       Date:  2010-10-15       Impact factor: 41.582

6.  DUBA: a deubiquitinase that regulates type I interferon production.

Authors:  Nobuhiko Kayagaki; Qui Phung; Salina Chan; Ruchir Chaudhari; Casey Quan; Karen M O'Rourke; Michael Eby; Eric Pietras; Genhong Cheng; J Fernando Bazan; Zemin Zhang; David Arnott; Vishva M Dixit
Journal:  Science       Date:  2007-11-08       Impact factor: 47.728

7.  Structural basis and specificity of human otubain 1-mediated deubiquitination.

Authors:  Mariola J Edelmann; Alexander Iphöfer; Masato Akutsu; Mikael Altun; Katalin di Gleria; Holger B Kramer; Edda Fiebiger; Sirano Dhe-Paganon; Benedikt M Kessler
Journal:  Biochem J       Date:  2009-03-01       Impact factor: 3.857

8.  Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses.

Authors:  Natalia Frias-Staheli; Nadia V Giannakopoulos; Marjolein Kikkert; Shannon L Taylor; Anne Bridgen; Jason Paragas; Juergen A Richt; Raymond R Rowland; Connie S Schmaljohn; Deborah J Lenschow; Eric J Snijder; Adolfo García-Sastre; Herbert Whiting Virgin
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

Review 9.  Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosis.

Authors:  Friedemann Weber; Ali Mirazimi
Journal:  Cytokine Growth Factor Rev       Date:  2008-11-21       Impact factor: 7.638

10.  Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease.

Authors:  Holger A Lindner; Viktoria Lytvyn; Hongtao Qi; Paule Lachance; Edmund Ziomek; Robert Ménard
Journal:  Arch Biochem Biophys       Date:  2007-07-14       Impact factor: 4.013

View more
  79 in total

1.  Arterivirus and nairovirus ovarian tumor domain-containing Deubiquitinases target activated RIG-I to control innate immune signaling.

Authors:  Puck B van Kasteren; Corrine Beugeling; Dennis K Ninaber; Natalia Frias-Staheli; Sander van Boheemen; Adolfo García-Sastre; Eric J Snijder; Marjolein Kikkert
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Architecture and regulation of negative-strand viral enzymatic machinery.

Authors:  Philip J Kranzusch; Sean P J Whelan
Journal:  RNA Biol       Date:  2012-07-01       Impact factor: 4.652

3.  Crystal structure of human ISG15 protein in complex with influenza B virus NS1B.

Authors:  Liang Li; Dongli Wang; Yinan Jiang; Jianfeng Sun; Senyan Zhang; Yuanyuan Chen; Xinquan Wang
Journal:  J Biol Chem       Date:  2011-07-13       Impact factor: 5.157

4.  Insights into the Porcine Reproductive and Respiratory Syndrome Virus Viral Ovarian Tumor Domain Protease Specificity for Ubiquitin and Interferon Stimulated Gene Product 15.

Authors:  Stephanie M Bester; Courtney M Daczkowski; Kay S Faaberg; Scott D Pegan
Journal:  ACS Infect Dis       Date:  2018-06-12       Impact factor: 5.084

5.  Inherent dynamics within the Crimean-Congo Hemorrhagic fever virus protease are localized to the same region as substrate interactions.

Authors:  Elan Z Eisenmesser; Glenn C Capodagli; Geoffrey S Armstrong; Michael J Holliday; Nancy G Isern; Fengli Zhang; Scott D Pegan
Journal:  Protein Sci       Date:  2015-01-28       Impact factor: 6.725

6.  Diversity of ubiquitin and ISG15 specificity among nairoviruses' viral ovarian tumor domain proteases.

Authors:  Glenn C Capodagli; Michelle K Deaton; Erica A Baker; Ryan J Lumpkin; Scott D Pegan
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

7.  Deubiquitinase function of arterivirus papain-like protease 2 suppresses the innate immune response in infected host cells.

Authors:  Puck B van Kasteren; Ben A Bailey-Elkin; Terrence W James; Dennis K Ninaber; Corrine Beugeling; Mazdak Khajehpour; Eric J Snijder; Brian L Mark; Marjolein Kikkert
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

8.  Biochemical and Structural Insights into the Preference of Nairoviral DeISGylases for Interferon-Stimulated Gene Product 15 Originating from Certain Species.

Authors:  M K Deaton; J V Dzimianski; C M Daczkowski; G K Whitney; N J Mank; M M Parham; E Bergeron; S D Pegan
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

9.  Crimean-Congo Hemorrhagic Fever Virus Suppresses Innate Immune Responses via a Ubiquitin and ISG15 Specific Protease.

Authors:  Florine E M Scholte; Marko Zivcec; John V Dzimianski; Michelle K Deaton; Jessica R Spengler; Stephen R Welch; Stuart T Nichol; Scott D Pegan; Christina F Spiropoulou; Éric Bergeron
Journal:  Cell Rep       Date:  2017-09-05       Impact factor: 9.423

10.  Fluorometric CCHFV OTU protease assay with potent inhibitors.

Authors:  Fatih Kocabas; Galip S Aslan
Journal:  Virus Genes       Date:  2015-07-09       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.